Mihai Dorin Vartolomei1, David D'Andrea2, Daher C Chade3, Francesco Soria2, Shoji Kimura4, Beat Foerster5, Mohammad Abufaraj6, Romain Mathieu7, Marco Moschini8, Morgan Rouprêt9, Alberto Briganti10, Pierre I Karakiewicz11, Shahrokh F Shariat12. 1. Department of Urology, Medical University of Vienna, Vienna, Austria; Department of Cell and Molecular Biology, University of Medicine, Pharmacy, Science and Technology, Tirgu Mures, Romania. 2. Department of Urology, Medical University of Vienna, Vienna, Austria. 3. Department of Urology, University of São Paulo Medical School and Institute of Cancer, São Paulo, Brazil. 4. Department of Urology, Medical University of Vienna, Vienna, Austria; Department of Urology, Jikei University School of Medicine, Tokyo, Japan. 5. Department of Urology, Medical University of Vienna, Vienna, Austria; Department of Urology, Kantonsspital Winterthur, Winterthur, Switzerland. 6. Department of Urology, Medical University of Vienna, Vienna, Austria; Division of Urology, Department of Special Surgery, Jordan University Hospital, The University of Jordan, Amman, Jordan. 7. Department of Urology, Medical University of Vienna, Vienna, Austria; Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria. 8. Department of Urology, Medical University of Vienna, Vienna, Austria; Department of Urology, Rennes University Hospital, Rennes, France; Klinik für Urologie, Luzerner Kantonsspital, Lucerne, Switzerland; Department of Urology, Urological Research Institute, Vita-Salute University, San Raffaele Scientific Institute, Milan, Italy. 9. Sorbonne Université, Paris, France. 10. Department of Urology, Urological Research Institute, Vita-Salute University, San Raffaele Scientific Institute, Milan, Italy. 11. Department of Urology, University of Montreal, Montreal, Quebec, Canada. 12. Department of Urology, Medical University of Vienna, Vienna, Austria; Karl Landsteiner Institute of Urology and Andrology, Vienna, Austria; Department of Urology, University of Texas Southwestern Medical Center, Dallas, TX; Department of Urology, Weill Cornell Medical College, New York, NY. Electronic address: shahrokh.shariat@meduniwien.ac.at.
Abstract
BACKGROUND: Serum cholinesterase (ChE) a serine hydrolase that catalyses the hydrolysis of esters of choline, is involved in cellular proliferation and differentiation, therefore affecting carcinogenesis. The aim of this study was to understand the prognostic role of preoperative serum ChE in patients with radiation-recurrent prostate cancer (CaP) treated with salvage radical prostatectomy (SRP). MATERIAL AND METHODS: This retrospective study included 214 patients with radiation-recurrent CaP treated with SRP from January 2007 to December 2015 at 5 academic centers. Patients were considered with abnormal/decreased ChE levels if <5 kU/l. Biochemical recurrence-free and metastases-free (MFS) survival analyses were performed. RESULTS: Median serum ChE level was 6.9 (interquartile range) 6-7.7) kU/l. Serum ChE level (<5 kU/l) was decreased in 25 (11.7%) patients. Decreased serum ChE level was associated with lower body mass index (P = 0.006) and metastasis to lymph nodes (P = 0.004). In multivariable analysis, continuous ChE was an independent predictor of MFS (hazard ratio [HR] 0.48, confidence interval [CI] 0.33-0.71, P < 0.001), overall survival (HR 0.68, CI 0.48-0.96, P = 0.03) and cancer-specific survival (HR 0.41, CI 0.2-0.84, P = 0.01). Serum ChE improved the C-index (by 2.54%) to 87.8% for prediction of overall survival and (by 3%) to 92% for prediction of MFS. CONCLUSION: Preoperative serum ChE is associated with the development of metastasis in patients with radiation-recurrent CaP who underwent SRP. The biological underpinning of this association with the biological and clinical aggressiveness of CaP needs to be further elucidated.
BACKGROUND: Serum cholinesterase (ChE) a serine hydrolase that catalyses the hydrolysis of esters of choline, is involved in cellular proliferation and differentiation, therefore affecting carcinogenesis. The aim of this study was to understand the prognostic role of preoperative serum ChE in patients with radiation-recurrent prostate cancer (CaP) treated with salvage radical prostatectomy (SRP). MATERIAL AND METHODS: This retrospective study included 214 patients with radiation-recurrent CaP treated with SRP from January 2007 to December 2015 at 5 academic centers. Patients were considered with abnormal/decreased ChE levels if <5 kU/l. Biochemical recurrence-free and metastases-free (MFS) survival analyses were performed. RESULTS: Median serum ChE level was 6.9 (interquartile range) 6-7.7) kU/l. Serum ChE level (<5 kU/l) was decreased in 25 (11.7%) patients. Decreased serum ChE level was associated with lower body mass index (P = 0.006) and metastasis to lymph nodes (P = 0.004). In multivariable analysis, continuous ChE was an independent predictor of MFS (hazard ratio [HR] 0.48, confidence interval [CI] 0.33-0.71, P < 0.001), overall survival (HR 0.68, CI 0.48-0.96, P = 0.03) and cancer-specific survival (HR 0.41, CI 0.2-0.84, P = 0.01). Serum ChE improved the C-index (by 2.54%) to 87.8% for prediction of overall survival and (by 3%) to 92% for prediction of MFS. CONCLUSION: Preoperative serum ChE is associated with the development of metastasis in patients with radiation-recurrent CaP who underwent SRP. The biological underpinning of this association with the biological and clinical aggressiveness of CaP needs to be further elucidated.
Authors: Fahad Quhal; Pawel Rajwa; Keiichiro Mori; Ekaterina Laukhtina; Nico C Grossmann; Victor M Schuettfort; Frederik König; Abdulmajeed Aydh; Reza S Motlagh; Satoshi Katayama; Hadi Mostafai; Benjamin Pradere; Giancarlo Marra; Paolo Gontero; Romain Mathieu; Pierre I Karakiewicz; Alberto Briganti; Shahrokh F Shariat; Axel Heidenreich Journal: Prostate Date: 2021-05-31 Impact factor: 4.104
Authors: Pawel Rajwa; Victor M Schuettfort; Fahad Quhal; Keiichiro Mori; Satoshi Katayama; Ekaterina Laukhtina; Benjamin Pradere; Reza Sari Motlagh; Hadi Mostafaei; Nico C Grossmann; Andreas Aulitzky; Andrzej Paradysz; Pierre I Karakiewicz; Harun Fajkovic; Kristin Zimmermann; Axel Heidenreich; Paolo Gontero; Shahrokh F Shariat Journal: World J Urol Date: 2021-05-17 Impact factor: 4.226